by | Feb 3, 2025 | Lupus Foundation of America, News & Events
The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene Therapeutics’ ALLO-329, an investigational allogenicCAR-T cell therapy. Researchers are preparing to a initiate the Phase 1 RESOLUTION trial in mid-2025...
by | Feb 1, 2025 | Lupus Foundation of America
Nyobie’s journey with lupus is a story of resilience, empowerment, and the transformative strength of finding her voice. Diagnosed in 2010 after a difficult 19-year journey through eight different doctors, Nyobie has lived through the complexities of a chronic illness...
by | Jan 30, 2025 | Lupus Foundation of America
The way we talk about lupus – to ourselves and with others – matters. Living with lupus can feel like a daily battle filled with uncertainty. Negative self-talk about this disease and its limitations can only weigh you down and make you feel worse. In our final blog...
by | Jan 24, 2025 | Lupus Foundation of America
On November 3rd, I ran the New York City Marathon. It was difficult, extraordinary, emotional and painful – not in the least because it was almost 3 years to the day that I got diagnosed with lupus.I’d argue that running a marathon is an extraordinary accomplishment...
by | Jan 24, 2025 | Lupus Foundation of America
This month we have been discussing mental health and wellness when you have lupus in a four-part blog series. This week we are sharing some strategies on talking about lupus and your experiences.Talking with friends, family and colleagues about living with lupus isn’t...
by | Jan 24, 2025 | Lupus Foundation of America, News & Events
An investigator-initiated Phase 1/2 trial of CNTY-101, an investigational therapy, has been announced for the treatment of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE) and lupus nephritis (LN). The trial, named the CARAMEL trial,...
